AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
nitrofurazone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| NO2 - derivatives | 1950 | 59-87-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 0.593 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.603 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 27.925 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 4.046 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 40.010 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 48.040 | % | High | 1 |
| herg | hERG pIC50 | 3.690 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.056 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.698 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 38.740 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GRK3,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,KIT,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2 | 77 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK2,CDK4,CDK9,DDR1,DYRK1B,GRK2,GSK3A,GSK3B,IRAK1,JAK2,MAP2K3,MAP2K6,MAP3K14,MAP3K21,MAPK7,MARK4,PRKDC,SIK2,STK33,SYK,TEK,TTK,UHMK1,ULK1 | 30 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 3.155 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 7.031 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 58.720 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.738 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 34.260 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 3.119 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 95.930 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 42.740 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1004.616 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 4, 1945 | FDA | SHIRE |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Joint dislocation | 255.20 | 52.01 | 130 | 14349 | 44452 | 90569516 |
| Seronegative arthritis | 246.25 | 52.01 | 97 | 14382 | 18137 | 90595831 |
| Prescribed underdose | 204.43 | 52.01 | 135 | 14344 | 74884 | 90539084 |
| Joint stiffness | 192.43 | 52.01 | 132 | 14347 | 77910 | 90536058 |
| Walking aid user | 181.51 | 52.01 | 96 | 14383 | 35410 | 90578558 |
| Wound infection | 179.10 | 52.01 | 143 | 14336 | 106259 | 90507709 |
| Retinitis | 171.56 | 52.01 | 95 | 14384 | 38363 | 90575605 |
| Lupus vulgaris | 170.62 | 52.01 | 100 | 14379 | 44959 | 90569009 |
| Laryngitis | 157.11 | 52.01 | 99 | 14380 | 50654 | 90563314 |
| Lupus-like syndrome | 155.53 | 52.01 | 97 | 14382 | 48749 | 90565219 |
| Visual impairment | 144.36 | 52.01 | 139 | 14340 | 132226 | 90481742 |
| Upper respiratory tract infection | 142.30 | 52.01 | 136 | 14343 | 128182 | 90485786 |
| Type 2 diabetes mellitus | 139.59 | 52.01 | 167 | 14312 | 203077 | 90410891 |
| Hypercholesterolaemia | 133.38 | 52.01 | 118 | 14361 | 100774 | 90513194 |
| Osteoporosis | 131.82 | 52.01 | 115 | 14364 | 96416 | 90517552 |
| Anti-cyclic citrullinated peptide antibody | 131.79 | 52.01 | 71 | 14408 | 27150 | 90586818 |
| Sciatica | 124.99 | 52.01 | 114 | 14365 | 101268 | 90512700 |
| Joint range of motion decreased | 121.40 | 52.01 | 128 | 14351 | 135515 | 90478453 |
| Spinal fusion surgery | 117.19 | 52.01 | 51 | 14428 | 12232 | 90601736 |
| Spondylitis | 116.45 | 52.01 | 53 | 14426 | 14125 | 90599843 |
| Road traffic accident | 115.38 | 52.01 | 112 | 14367 | 107514 | 90506454 |
| Hepatic cirrhosis | 110.61 | 52.01 | 87 | 14392 | 63166 | 90550802 |
| Adjustment disorder with depressed mood | 110.04 | 52.01 | 83 | 14396 | 56670 | 90557298 |
| Dislocation of vertebra | 108.84 | 52.01 | 82 | 14397 | 55886 | 90558082 |
| Foot deformity | 108.54 | 52.01 | 84 | 14395 | 59567 | 90554401 |
| Hip arthroplasty | 108.49 | 52.01 | 93 | 14386 | 76115 | 90537853 |
| Exostosis | 108.13 | 52.01 | 80 | 14399 | 53054 | 90560914 |
| Liver function test increased | 107.68 | 52.01 | 97 | 14382 | 84758 | 90529210 |
| Bone erosion | 106.04 | 52.01 | 79 | 14400 | 52942 | 90561026 |
| Drug ineffective | 105.59 | 52.01 | 45 | 14434 | 1384253 | 89229715 |
| Prescribed overdose | 101.65 | 52.01 | 100 | 14379 | 97525 | 90516443 |
| Osteoarthritis | 101.54 | 52.01 | 140 | 14339 | 195590 | 90418378 |
| Red blood cell sedimentation rate increased | 98.12 | 52.01 | 91 | 14388 | 82504 | 90531464 |
| Deep vein thrombosis postoperative | 93.90 | 52.01 | 83 | 14396 | 70726 | 90543242 |
| Disability | 93.51 | 52.01 | 66 | 14413 | 40679 | 90573289 |
| Lower limb fracture | 90.21 | 52.01 | 88 | 14391 | 84925 | 90529043 |
| Ear infection | 87.01 | 52.01 | 79 | 14400 | 69696 | 90544272 |
| Swollen joint count increased | 85.63 | 52.01 | 97 | 14382 | 111109 | 90502859 |
| Pulmonary fibrosis | 84.88 | 52.01 | 95 | 14384 | 107408 | 90506560 |
| Autoimmune disorder | 84.36 | 52.01 | 81 | 14398 | 76663 | 90537305 |
| Irritable bowel syndrome | 83.90 | 52.01 | 132 | 14347 | 207316 | 90406652 |
| Wheezing | 83.47 | 52.01 | 142 | 14337 | 237938 | 90376030 |
| Grip strength decreased | 78.60 | 52.01 | 85 | 14394 | 92491 | 90521477 |
| Knee arthroplasty | 73.48 | 52.01 | 78 | 14401 | 83104 | 90530864 |
| Fibromyalgia | 70.92 | 52.01 | 122 | 14357 | 206147 | 90407821 |
| Urticaria | 69.69 | 52.01 | 154 | 14325 | 312580 | 90301388 |
| Delirium | 68.66 | 52.01 | 84 | 14395 | 104275 | 90509693 |
| Oedema | 68.24 | 52.01 | 118 | 14361 | 200177 | 90413791 |
| Injury | 65.58 | 52.01 | 115 | 14364 | 197234 | 90416734 |
| Amnesia | 62.91 | 52.01 | 82 | 14397 | 108423 | 90505545 |
| Mobility decreased | 62.20 | 52.01 | 129 | 14350 | 250605 | 90363363 |
| Fall | 61.33 | 52.01 | 4 | 14475 | 481806 | 90132162 |
| Drug-induced liver injury | 59.90 | 52.01 | 73 | 14406 | 90245 | 90523723 |
| Wound | 59.53 | 52.01 | 142 | 14337 | 302838 | 90311130 |
| Psoriasis | 58.29 | 52.01 | 93 | 14386 | 147661 | 90466307 |
| Gait inability | 57.52 | 52.01 | 92 | 14387 | 146364 | 90467604 |
| Rheumatic fever | 57.17 | 52.01 | 94 | 14385 | 153027 | 90460941 |
| Tachycardia | 56.46 | 52.01 | 95 | 14384 | 157578 | 90456390 |
| Helicobacter infection | 55.41 | 52.01 | 116 | 14363 | 226734 | 90387234 |
| Liver injury | 54.86 | 52.01 | 98 | 14381 | 170469 | 90443499 |
| Rheumatoid factor positive | 54.41 | 52.01 | 98 | 14381 | 171552 | 90442416 |
| C-reactive protein increased | 54.26 | 52.01 | 101 | 14378 | 181288 | 90432680 |
| Hypoaesthesia | 54.07 | 52.01 | 140 | 14339 | 314070 | 90299898 |
| Breast cancer stage III | 52.37 | 52.01 | 66 | 14413 | 84381 | 90529587 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Sleep disorder due to general medical condition, insomnia type | 54.63 | 36.37 | 38 | 3806 | 105605 | 110479850 |
| Sciatica | 51.94 | 36.37 | 35 | 3809 | 92364 | 110493091 |
| Type 2 diabetes mellitus | 48.85 | 36.37 | 44 | 3800 | 177188 | 110408267 |
| Fibromyalgia | 46.26 | 36.37 | 42 | 3802 | 170867 | 110414588 |
| Road traffic accident | 42.76 | 36.37 | 33 | 3811 | 107365 | 110478090 |
| Seronegative arthritis | 41.34 | 36.37 | 16 | 3828 | 13161 | 110572294 |
| Helicobacter infection | 38.42 | 36.37 | 39 | 3805 | 181838 | 110403617 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B05CA03 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS IRRIGATING SOLUTIONS Antiinfectives |
| ATC | D08AF01 | DERMATOLOGICALS ANTISEPTICS AND DISINFECTANTS ANTISEPTICS AND DISINFECTANTS Nitrofuran derivatives |
| ATC | D09AA03 | DERMATOLOGICALS MEDICATED DRESSINGS MEDICATED DRESSINGS Medicated dressings with antiinfectives |
| ATC | P01CC02 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS Nitrofuran derivatives |
| ATC | S01AX04 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Other antiinfectives |
| ATC | S02AA02 | SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
Related Drugs by ATC class:
B05CA Antiinfectives 8 drugs
D09AA Medicated dressings with antiinfectives 11 drugs
P01CC Nitrofuran derivatives 1 drug
S01AX Other antiinfectives 13 drugs
S02AA Antiinfectives 17 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Klebsiella cystitis | indication | 60867007 | |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Staphylococcus Saprophyticus Urinary Tract Infection | indication | ||
| Enterococcus Urinary Tract Infection | indication | ||
| Staphylococcus Aureus Urinary Tract Infection | indication | ||
| Enterobacter Cystitis | indication | ||
| Prevention of Bacterial Urinary Tract Infection | off-label use | ||
| Anuria | contraindication | 2472002 | DOID:2983 |
| Acute hepatitis | contraindication | 37871000 | |
| Vitamin B deficiency | contraindication | 47903000 | |
| Fibrosis of lung | contraindication | 51615001 | DOID:3770 |
| Obstructive hyperbilirubinemia | contraindication | 59848001 | |
| Interstitial pneumonia | contraindication | 64667001 | |
| Optic neuritis | contraindication | 66760008 | DOID:1210 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Chronic hepatitis | contraindication | 76783007 | DOID:2237 |
| Oliguria | contraindication | 83128009 | |
| Cholestatic hepatitis | contraindication | 95556007 | |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
| Cobalamin deficiency | contraindication | 190634004 | |
| Impaired renal function disorder | contraindication | 197663003 | |
| Drug-induced hepatitis | contraindication | 235876009 | |
| Peripheral nerve disease | contraindication | 302226006 | |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Surface bacterial infections of wounds | Indication |
| Cats | Surface bacterial infections of burns | Indication |
| Cats | Surface bacterial infections of skin ulcers and abscesses | Indication |
| Dogs | Surface bacterial infections of wounds | Indication |
| Dogs | Surface bacterial infections of burns | Indication |
| Dogs | Surface bacterial infections of skin ulcers and abscesses | Indication |
| Horses | Surface bacterial infections of wounds | Indication |
| Horses | Surface bacterial infections of burns | Indication |
| Horses | Surface bacterial infections of skin ulcers and abscesses | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| NFZ Puffer | Neogen Corp. | 1 |
| Fura Ointment | Farnam Companies Inc. | 1 |
| Fura-Septin Soluble Dressing | Bimeda Animal Health Limited | 1 |
| Nitrofurazone Dressing | Cronus Pharma Specialities India Private Limited | 1 |
| Nitrofurazone Soluble Powder | Cronus Pharma Specialities India Private Limited | 1 |
| Nitrofurazone Ointment | Bimeda Animal Health Limited | 1 |
| Nitrofurazone Anesthetic Dress. | Med-Pharmex Inc. | 2 |
| Fura-Zone | Squire Laboratories Inc. | 1 |
| Nitrofurazone Ointment | Sparhawk Laboratories Inc. | 1 |
| NFZ Wound Dressing | Neogen Corp. | 1 |
| Nitrofurazone Soluble Dressing | Med-Pharmex Inc. | 1 |
| Nitrofurazone Soluble Dressing | First Priority Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.85 | acidic |
| pKa2 | 12.47 | acidic |
| pKa3 | 0.0 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucose-6-phosphate 1-dehydrogenase | Enzyme | WOMBAT-PK | |||||||
| Sterile alpha and TIR motif-containing protein 1 | Enzyme | IC50 | 4.05 | CHEMBL | |||||
| Snake venom metalloproteinase Bap1 | Enzyme | IC50 | 4.06 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018879 | VUID |
| N0000147174 | NUI |
| D00862 | KEGG_DRUG |
| 4018879 | VANDF |
| C0028157 | UMLSCUI |
| NFZ | PDB_CHEM_ID |
| CHEMBL869 | ChEMBL_ID |
| DB00336 | DRUGBANK_ID |
| D009583 | MESH_DESCRIPTOR_UI |
| 5447130 | PUBCHEM_CID |
| 4160 | INN_ID |
| X8XI70B5Z6 | UNII |
| 227727 | RXNORM |
| 2323 | MMSL |
| 402 | MMSL |
| 5182 | MMSL |
| 002857 | NDDF |
| 332799007 | SNOMEDCT_US |
| 87097009 | SNOMEDCT_US |
| CHEBI:44368 | CHEBI |
| 12366 | IUPHAR_LIGAND_ID |
| X8XI70B5Z6 | INXIGHT DRUGS |
Pharmaceutical products:
None